Thymic carcinomas are extremely infrequent neoplasms (15% of all thymic epithelial tumors). Basaloid carcinoma is a peculiar tumor that represents no more than 2% of those infrequent thymic carcinomas. Surgical excision is the recommended treatment. As it's extremely rare, there is no evidence of the impact of different modalities of treatment. There are no reported cases that did not include surgery as part of their management. We herein present a case of an unresectable thymic basaloid carcinoma treated only with concurrent chemotherapy and radiotherapy that obtained a complete remission and free of disease after 2 years.
Introduction
Thymic neoplasms are rare tumors with an incidence of less than 1% of all adult cancers. Amongst those unusual tumors, thymic epithelial neoplasms include thymomas and thymic carcinomas. Carcinomas are extremely infrequent, representing only about 15% to 20% of all thymic epithelial tumors. Thymic basaloid carcinoma is a greatly peculiar tumor variant that represents no more than 2% of those infrequent thymic carcinomas and only a few cases have been reported in the literature. Surgical excision is the recommended treatment and has been performed for almost all previously published cases. In early studies [1] , evaluation of various treatment modalities used to treat patients with all types of thymic carcinomas did not yield any statistically significant correlations with survival. As basaloid carcinoma is extremely rare, there is no evidence of the impact of different modalities of treatment. To our knowledge, there are no reported cases that did not include surgery as part of their management. We herein present a case of an unresectable thymic basaloid carcinoma treated only with concurrent chemotherapy and radiotherapy that obtained a complete remission and free of disease after 2 years. [6] . A Cochrane revision in 2013 [7] showed that the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy but that there were no randomized control trials (RCTs) eligible for inclusion in that review. Recently, Song described seven patients who received paclitaxel plus carboplatin regimen as secondline and five as third-line chemotherapy with or without surgical resection (none of them TBC). They showed that the regimen of paclitaxel plus carboplatin was active for advanced thymic carcinoma patients as salvage chemotherapy with a response rate of 25.0% and median PFS of 3.5 months [8] . Nonaka et al showed in a study of 14 patients that those who received radiotherapy had a better outcome than the patients who did not, although the number of patients was too small and no patients who received radiotherapy to the mediastinum in the course of the initial treatment developed recurrence within the radiation field. The authors interpreted that these findings strongly suggest that radiotherapy plays an important role in treating thymic carcinoma and can reduce local recurrence.
Patient and observation
Only recently, a group of the Niigata University Medical and Dental Hospital, reported a case of thymic basaloid carcinoma [9] 
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